Skip to main content

Table 3 EQ-5D scores at each study visit according to treatment received (Level 1 = no problem; Level 2 = medium; Level 3 = severe)

From: Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study

EQ-5D

Baseline

3 months

6 months

9 months

Non-bDMARDs

bDMARDs

Non-bDMARDs

bDMARDs

Non-bDMARDs

bDMARDs

Non-bDMARDs

bDMARDs

Mobility, n (%)

N = 86

N = 123

N = 68

N = 115

N = 73

N = 121

N = 78

N = 119

 Level 1

43 (50.0)

50 (40.7)

40 (58.8)

45 (39.1)

49 (67.1)

48 (39.7)

47 (60.3)

54 (45.4)

 Level 2

43 (50.0)

72 (58.5)

28 (41.2)

70 (60.9)

24 (32.9)

73 (60.3)

31 (39.7)

63 (52.9)

 Level 3

0 (0.0)

1 (0.8)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

2 (1.7)

Self-care, n (%)

N = 86

N = 123

N = 68

N = 115

N = 73

N = 121

N = 78

N = 119

 Level 1

60 (69.8)

77 (62.6)

45 (66.2)

68 (59.1)

45 (61.6)

63 (52.1)

46 (59.0)

61 (51.3)

 Level 2

26 (30.2)

46 (37.4)

23 (33.8)

47 (40.9)

28 (38.4)

58 (47.9)

32 (41.0)

56 (47.1)

 Level 3

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

2 (1.7)

Usual activities, n (%)

N = 85

N = 123

N = 68

N = 115

N = 73

N = 121

N = 78

N = 119

 Level 1

33 (38.8)

39 (31.7)

34 (50.0)

41 (35.7)

34 (46.6)

37 (30.6)

35 (44.9)

32 (26.9)

 Level 2

50 (58.8)

84 (68.3)

34 (50.0)

73 (63.5)

39 (53.4)

82 (67.8)

43 (55.1)

85 (71.4)

 Level 3

2 (2.4)

0 (0.0)

0 (0.0)

1 (0.9)

0 (0.0)

2 (1.7)

0 (0.0)

2 (1.7)

Pain/discomfort, n (%)

N = 86

N = 123

N = 68

N = 115

N = 73

N = 121

N = 78

N = 119

 Level 1

28 (32.6)

33 (26.8)

28 (41.2)

25 (21.7)

33 (45.2)

25 (20.7)

38 (48.7)

25 (21.0)

 Level 2

56 (65.1)

80 (65.0)

38 (55.9)

84 (73.0)

39 (53.4)

88 (72.7)

36 (46.2)

82 (68.9)

 Level 3

2 (2.3)

10 (8.1)

2 (2.9)

6 (5.2)

1 (1.4)

8 (6.6)

4 (5.1)

12 (10.1)

Anxiety/depression, n (%)

N = 86

N = 123

N = 68

N = 115

N = 73

N = 121

N = 78

N = 119

 Level 1

31 (36.0)

43 (35.0)

30 (44.1)

42 (36.5)

38 (52.1)

34 (28.1)

37 (47.4)

28 (23.5)

 Level 2

36 (41.9)

50 (40.7)

30 (44.1)

47 (40.9)

30 (41.1)

60 (49.6)

31 (39.7)

60 (50.4)

 Level 3

19 (22.1)

30 (24.4)

8 (11.8)

26 (22.6)

5 (6.8)

27 (22.3)

10 (12.8)

31 (26.1)

EQ VAS score, Mean ± SD

N = 86

N = 123

N = 68

N = 115

N = 73

N = 120

N = 78

N = 119

67.0 ± 20.2

66.0 ± 20.2

71.4 ± 20.9

67.2 ± 19.3

75.9 ± 18.8

66.7 ± 18.7

75.9 ± 19.0

67.7 ± 18.8

Total EQ-5D score, Mean ± SD

N = 85

N = 123

N = 68

N = 115

N = 73

N = 121

N = 78

N = 119

0.60 ± 0.32

0.54 ± 0.32

0.69 ± 0.31

0.56 ± 0.30

0.73 ± 0.26

0.54 ± 0.30

0.68 ± 0.32

0.50 ± 0.34

Adjusted total EQ-5D scorea, Least-squares mean ± SE

N = 85

N = 123

N = 68

N = 115

N = 73

N = 121

N = 78

N = 119

0.59 ± 0.04

0.55 ± 0.03

0.66 ± 0.03

0.55 ± 0.03

0.70 ± 0.03

0.53 ± 0.03

0.65 ± 0.04

0.49 ± 0.03

  1. bDMARD biologic disease-modifying antirheumatic drug, EQ-5D Euro Quality of Life-5 dimensions, SD standard deviation, SE standard error, VAS visual analog scale
  2. aEQ-5D index score adjusted for baseline covariates: gender and smoking status